Compare CW & BNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CW | BNTX |
|---|---|---|
| Founded | 1929 | 2008 |
| Country | United States | Germany |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.2B | 22.8B |
| IPO Year | 1994 | 2019 |
| Metric | CW | BNTX |
|---|---|---|
| Price | $663.03 | $85.61 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 13 |
| Target Price | ★ $603.00 | $134.15 |
| AVG Volume (30 Days) | 260.4K | ★ 1.3M |
| Earning Date | 05-06-2026 | 03-10-2026 |
| Dividend Yield | ★ 0.14% | N/A |
| EPS Growth | ★ 21.99 | N/A |
| EPS | ★ 12.87 | N/A |
| Revenue | ★ $2,391,336,000.00 | N/A |
| Revenue This Year | $10.39 | N/A |
| Revenue Next Year | $7.87 | $4.76 |
| P/E Ratio | $51.71 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $266.88 | $79.81 |
| 52 Week High | $730.12 | $124.00 |
| Indicator | CW | BNTX |
|---|---|---|
| Relative Strength Index (RSI) | 44.25 | 33.71 |
| Support Level | $640.00 | $79.81 |
| Resistance Level | $676.54 | $113.12 |
| Average True Range (ATR) | 27.26 | 2.69 |
| MACD | -3.78 | -0.31 |
| Stochastic Oscillator | 26.53 | 34.83 |
Curtiss-Wright Corporation delivers engineered products and services to commercial, defence, power generation, and other industrial markets. It offers industrial vehicle components, control systems, weapons handling systems, pumps, valves, and other solutions. The company has three reportable segments based on the markets serviced: Naval & Power, which provides coolant pumps, power-dense compact motors, generators, secondary propulsion systems, pumps, pump seals, valves, control rod drive mechanisms, and fastening systems that also generate maximum revenue for the company; its other segments are Aerospace & Industrial and Defense Electronics. Geographically, the company generates its key revenue from the United States of America, followed by the United Kingdom and other countries.
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including covid. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens and neoantigens; monospecific and bispecific antibodies; and antibody-drug conjugates, or ADCs. Comirnaty, its Pfizer-partnered covid vaccine, is its first commercialized product.